ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive. Shares in New York traded 5% higher ahead of the morning bell ...

Explore the latest research on glaucoma treatment and the role of immune cells in eye pressure regulation for better outcomes ...

Inventor Malik Y. Kahook, MD, collaborates with CU Anschutz Innovations to bring the product, which has the potential to ...

Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S.

The 2026 Shaffer Research Grants were awarded to Kun-Che Chang, PhD, Shruthi Karnam, PhD, Kate Keller, PhD, Naoki Kiyota, MD, PhD, Gillian McLellan, PhD, Kiyoharu Miyagishima, PhD, Kerstin Nundel, PhD ...

Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.

Certain diet and lifestyle measures, such as being physically active, may have beneficial effects on glaucoma, including improving blood flow to the eyes and lowering eye pressure. Herbal supplements ...

While age is a major risk factor, glaucoma can occur at any stage of life, including infancy, childhood, adolescence, and ...

AI could revolutionise glaucoma detection. Here’s 6 things everyone should know - Age and family history are significant risk factors for developing glaucoma ...